Daiichi Life Insurance Co. Ltd. Buys New Stake in United Therapeutics Corporation $UTHR

Daiichi Life Insurance Co. Ltd. bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 8,277 shares of the biotechnology company’s stock, valued at approximately $4,485,000.

A number of other institutional investors also recently added to or reduced their stakes in UTHR. Torren Management LLC bought a new position in shares of United Therapeutics in the fourth quarter worth $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC lifted its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. lifted its holdings in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new position in United Therapeutics in the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at approximately $23,631,280.08. This trade represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $526.96, for a total transaction of $5,006,120.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $170,968,483.28. This trade represents a 2.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 442,575 shares of company stock valued at $239,326,330. Company insiders own 8.60% of the company’s stock.

Analyst Ratings Changes

UTHR has been the topic of several research analyst reports. Bank of America lowered their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. JPMorgan Chase & Co. increased their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $513.12 on Monday. United Therapeutics Corporation has a twelve month low of $302.19 and a twelve month high of $609.35. The company has a market capitalization of $22.01 billion, a price-to-earnings ratio of 18.36, a PEG ratio of 1.74 and a beta of 0.59. The firm has a 50-day moving average of $533.08 and a two-hundred day moving average of $537.80.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter last year, the firm posted $6.41 EPS. As a group, research analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.